Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Suk Kyeong Kim  (Kim SK) 3 Articles
Drug/Regimen
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Young Min, Sungrae Kim
Diabetes Metab J. 2022;46(6):855-865.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0264
  • 8,157 View
  • 326 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Thiazolidinediones (TZDs) have been associated with various safety concerns including weight gain, bladder cancer, and congestive heart failure (CHF). This study evaluated the efficacy and safety of lobeglitazone, a novel TZD in patients with type 2 diabetes mellitus (T2DM) in real practice.
Methods
In this non-interventional, multi-center, retrospective, and observational study conducted at 15 tertiary or secondary referral hospitals in Korea, a total of 2,228 patients with T2DM who received lobeglitazone 0.5 mg for more than 1 year were enrolled.
Results
Overall adverse events (AEs) occurred in 381 patients (17.10%) including edema in 1.97% (n=44). Cerebrovascular and cardiovascular diseases were identified in 0.81% (n=18) and 0.81% (n=18), respectively. One case of CHF was reported as an AE. Edema occurred in 1.97% (n=44) of patients. Hypoglycemia occurred in 2.47% (n=55) of patients. Fracture occurred in 1.17% (n=26) of all patients. Lobeglitazone significantly decreased HbA1c level, resulting in a mean treatment difference of -1.05%± 1.35% (P<0.001), and decreased total cholesterol, triglyceride, and low-density lipoprotein cholesterol. However, it increased high-density lipoprotein cholesterol, regardless of statin administration. The patients who received lobeglitazone 0.5 mg showed an apparent reduction in glycosylated hemoglobin (HbA1c) from baseline during the first 6 months of treatment. The HbA1c levels remained stable between months 6 and 42.
Conclusion
Lobeglitazone has long-term safety profile, good glycemic-lowering effect and long-term durability of glycemic control in real-world clinical settings.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
    Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
  • Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
  • Lobeglitazone

    Reactions Weekly.2023; 1948(1): 262.     CrossRef
  • Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Lobeglitazone and Its Therapeutic Benefits: A Review
    Balamurugan M, Sarumathy S, Robinson R
    Cureus.2023;[Epub]     CrossRef
  • Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection
    Eun-Hee Cho
    Diabetes & Metabolism Journal.2022; 46(6): 827.     CrossRef
Clinical Care/Education
Is an Oral Glucose Tolerance Test Still Valid for Diagnosing Diabetes Mellitus?
Dong-Lim Kim, Sun-Doo Kim, Suk Kyeong Kim, Sooyoun Park, Kee-Ho Song
Diabetes Metab J. 2016;40(2):118-128.   Published online November 20, 2015
DOI: https://doi.org/10.4093/dmj.2016.40.2.118
  • 5,603 View
  • 72 Download
  • 23 Web of Science
  • 20 Crossref
AbstractAbstract PDFPubReader   
Background

We evaluated the diagnostic rate of diabetes using fasting plasma glucose (FPG), 2-hour plasma glucose (2h PG) after 75 g oral glucose tolerance test (OGTT), and glycosylated hemoglobin (HbA1c) levels, and we elucidated the pathophysiologic characteristics and risk factors that give rise to diabetes in patients with prediabetes.

Methods

The data of 236 patients who had the OGTT at Konkuk University Hospital were analyzed. Fasting, 30, and 120 minutes blood glucose levels and insulin levels were measured. The diagnostic rate of diabetes was assessed using FPG, 2h PG, and HbA1c levels. The clinical data and insulin resistance and secretion evaluations were compared using indexes according to the fasting glucose level.

Results

Among 236 subjects, 97 (41.1%) were diabetics and 102 (43.2%) were prediabetics. The rate of diabetes diagnosis by one of the individual criteria was 56.7%, 53.6%, and 84.5% for FPG, HbA1c, and 2h PG, respectively. When two criteria were used to diagnose diabetes, 72.2% of the diabetic patients were identified by FPG and HbA1c, while 100% were identified by FPG and 2h PG, and 91.7% were identified by 2h PG and HbA1c. The HbA1c cut-off value for 2h PG ≥200 mg/dL was 6.1%, and the FPG cut-off value was 115 mg/dL. In impaired fasting glucose subjects, the HbA1c level, Matsuda index, and insulinogenic index were associated with risk of occurrence of overt diabetes (P<0.01).

Conclusion

This study suggests that performing additional OGTT for patients with FPG ≥110 mg/dL or HbA1c ≥6.1% is helpful to reclassify their glucose tolerance status and evaluate their potential for progressing to overt diabetes.

Citations

Citations to this article as recorded by  
  • The effect of preprandial versus postprandial physical activity on glycaemia: Meta-analysis of human intervention studies
    Romy Slebe, Eva Wenker, Linda J. Schoonmade, Emma J. Bouman, Denis P. Blondin, David J.T. Campbell, André C. Carpentier, Joris Hoeks, Parminder Raina, Patrick Schrauwen, Mireille J. Serlie, Dirk Jan Stenvers, Renée de Mutsert, Joline W.J. Beulens, Femke R
    Diabetes Research and Clinical Practice.2024; 210: 111638.     CrossRef
  • Dysglycaemia prediction using readily available clinical, anthropometric, and biochemical measurements
    R. Guizar-Heredia, M. Guevara-Cruz, M. Aguilar-López, L.E. González-Salazar, I. Medina-Vera, L. Arteaga-Sánchez, E. Pichardo-Ontiveros, A.E. Serralde-Zúñiga, A. Diaz-Villaseñor, A. Ávila-Nava, N. Torres, A.R. Tovar
    Clinical Nutrition Open Science.2024; 55: 91.     CrossRef
  • Assessing blood sugar measures for predicting new-onset diabetes and cardiovascular disease in community-dwelling adults
    Jung-Hwan Kim, Yaeji Lee, Chung-Mo Nam, Yu-Jin Kwon, Ji-Won Lee
    Endocrine.2024;[Epub]     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
    Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang
    Diabetes & Metabolism Journal.2024; 48(4): 546.     CrossRef
  • Early prediction of gestational diabetes mellitus using first trimester maternal serum pregnancy‐associated plasma protein‐a: A cross‐sectional study
    Maedeh Amini, Anoshirvan Kazemnejad, Aliakbar Rasekhi, Azam Amirian, Nourossadat Kariman
    Health Science Reports.2024;[Epub]     CrossRef
  • Dichotomy in the Impact of Elevated Maternal Glucose Levels on Neonatal Epigenome
    Ives Yubin Lim, Xinyi Lin, Ai Ling Teh, Yonghui Wu, Li Chen, Menglan He, Shiao-Yng Chan, Julia L MacIsaac, Jerry K Y Chan, Kok Hian Tan, Mary Foong Fong Chong, Michael S Kobor, Keith M Godfrey, Michael J Meaney, Yung Seng Lee, Johan G Eriksson, Peter D Gl
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(3): e1277.     CrossRef
  • Imaging evaluation of the pancreas in diabetic patients
    Ni Zeng, Yi Wang, Yue Cheng, Zixing Huang, Bin Song
    Abdominal Radiology.2022; 47(2): 715.     CrossRef
  • The Impact of Financial Incentives on Behavior and Self-Management of Uncontrolled Type 2 Diabetes: Pre- and Post-Quasiexperimental Study
    Dalal Abdulaziz Al Kathiry, Fatima Al Slail, Khaled Al-Surimi, Raghib Abusaris
    Global Journal on Quality and Safety in Healthcare.2021; 4(3): 88.     CrossRef
  • Practice Patterns in the Acceptance of Medically Complex Living Kidney Donors with Obesity, Hypertension, Family History of Kidney Disease, or Donor-Recipient Age Discrepancy
    Ziad Arabi, Muhammad Bukhari, Abdullah Hamad, Abdulrahman Altheaby, Saleh Kaysi
    Avicenna Journal of Medicine.2021; 11(04): 172.     CrossRef
  • Secretagogin is Related to Insulin Secretion but Unrelated to Gestational Diabetes Mellitus Status in Pregnancy
    Carola Deischinger, Jürgen Harreiter, Karoline Leitner, Dagmar Bancher-Todesca, Sabina Baumgartner-Parzer, Alexandra Kautzky-Willer
    Journal of Clinical Medicine.2020; 9(7): 2277.     CrossRef
  • Hypoglycemic activity of extracts of Chamaecyparis obtusa var. formosana leaf in rats with hyperglycemia induced by high-fat diets and streptozotocin
    Chia-Yun Hsu, Gong-Min Lin, Shang-Tzen Chang
    Journal of Traditional and Complementary Medicine.2020; 10(4): 389.     CrossRef
  • Optimal fasting plasma glucose and haemoglobin A1c levels for screening of prediabetes and diabetes according to 2‐hour plasma glucose in a high‐risk population: The Korean Diabetes Prevention Study
    Seon‐Ah Cha, Suk Chon, Jae‐Seung Yun, Sang Youl Rhee, Sun‐Young Lim, Kun‐Ho Yoon, Yu‐Bae Ahn, Seung‐Hyun Ko, Jeong‐Taek Woo, Jin‐Hee Lee
    Diabetes/Metabolism Research and Reviews.2020;[Epub]     CrossRef
  • Prediction of type 2 diabetes mellitus using fasting plasma glucose and HbA1c levels among individuals with impaired fasting plasma glucose: a cross-sectional study in Thailand
    Tullaya Sitasuwan, Raweewan Lertwattanarak
    BMJ Open.2020; 10(11): e041269.     CrossRef
  • The effect of oral glucose tolerance testing on changes in arterial stiffness and blood pressure in elderly women with hypertension and relationships between the stage of diabetes and physical fitness levels
    Jaesong Lee, Wonil Park, Eunsook Sung, Bokbeom Kim, Nahyun Kim, Saejong Park, Chulho Shin, Jonghoon Park
    Physical Activity and Nutrition.2020; 24(4): 34.     CrossRef
  • From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research
    Radia Khan, Zoey Chua, Jia Tan, Yingying Yang, Zehuan Liao, Yan Zhao
    Medicina.2019; 55(9): 546.     CrossRef
  • Molecular imaging of β-cells: diabetes and beyond
    Weijun Wei, Emily B. Ehlerding, Xiaoli Lan, Quan-Yong Luo, Weibo Cai
    Advanced Drug Delivery Reviews.2019; 139: 16.     CrossRef
  • Validity of the FINDRISC as a prediction tool for diabetes in a contemporary Norwegian population: a 10-year follow-up of the HUNT study
    Anne Jølle, Kristian Midthjell, Jostein Holmen, Sven Magnus Carlsen, Jaakko Tuomilehto, Johan Håkon Bjørngaard, Bjørn Olav Åsvold
    BMJ Open Diabetes Research & Care.2019; 7(1): e000769.     CrossRef
  • HbA1c Cutoff for Prediabetes and Diabetes Based on Oral Glucose Tolerance Test in Obese Children and Adolescents
    Hyo-Kyoung Nam, Won Kyoung Cho, Jae Hyun Kim, Young-Jun Rhie, Sochung Chung, Kee-Hyoung Lee, Byung-Kyu Suh
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Detection of glucose metabolism disorders in coronary patients enrolled in cardiac rehabilitation: Is glycated haemoglobin useful? Data from the prospective REHABDIAB study
    Sopio Tatulashvili, Bénédicte Patois-Vergès, Amandine Nguyen, Marie-Cécile Blonde, Bruno Vergès
    European Journal of Preventive Cardiology.2018; 25(5): 464.     CrossRef
  • Imaging in pancreatic disease
    Julien Dimastromatteo, Teresa Brentnall, Kimberly A. Kelly
    Nature Reviews Gastroenterology & Hepatology.2017; 14(2): 97.     CrossRef
The Association between Midnight Salivary Cortisol and Metabolic Syndrome in Korean Adults
Yun-Mi Jang, Eun Jung Lee, Dong Lim Kim, Suk Kyeong Kim, Kee-Ho Song
Diabetes Metab J. 2012;36(3):245-250.   Published online June 14, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.3.245
  • 4,451 View
  • 25 Download
  • 6 Crossref
AbstractAbstract PDFPubReader   
Background

The common characteristics of metabolic syndrome (MetS) and Cushing's syndrome suggest that excess cortisol may be involved in the pathogenesis of MetS. Salivary cortisol measurements are simple and can be surrogates for plasma free cortisol, which is the most biologically active form. We evaluated the association between levels of midnight salivary cortisol and MetS in Korean adults.

Methods

A total of 46 subjects, aged 20 to 70 years, who visited the Health Care Center at Konkuk University Hospital from August 2008 to August 2009 were enrolled. We compared the levels of midnight salivary cortisol in subjects with MetS with those in subjects without MetS. We analyzed the associations between midnight salivary cortisol levels and components of MetS.

Results

Midnight salivary cortisol levels were higher in the MetS group (70±42.4 ng/dL, n=12) than that in the group without MetS (48.1±36.8 ng/dL, n=34) (P=0.001). Positive correlations were observed between midnight salivary cortisol levels and waist circumference, fasting blood glucose, and homeostasis model assessment of insulin resistance. The risk for MetS was significantly higher in subjects with midnight salivary cortisol levels ≥100 ng/dL than in those with levels <50 ng/dL (odds ratio, 5.9; 95% confidence interval, 2.35 to 36.4).

Conclusion

The results showed a positive correlation between midnight salivary cortisol levels and MetS, suggesting that hypercortisolism may be related to MetS.

Citations

Citations to this article as recorded by  
  • Evaluation of salivary endothelin-1 as a biomarker for oral cancer and precancer
    Sumaiya Irfan, Noorin Zaidi, Kshama Tiwari, Nirupma Lal, Anand Narayan Srivastava, Shivangi Singh
    Journal of Cancer Research and Therapeutics.2024; 20(5): 1420.     CrossRef
  • Association of primary allostatic load mediators and metabolic syndrome (MetS): A systematic review
    Francis Osei, Andrea Block, Pia-Maria Wippert
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Salivary cortisol levels during Ramadan fasting in hydrocortisone-treated secondary adrenal insufficiency patients
    Melika Chihaoui, Wiem Madhi, Meriem Yazidi, Bessem Hammami, Ibtissem Oueslati, Nadia Khessairi, Wafa Grira, Amina Bibi, Moncef Feki, Fatma Chaker
    Endocrine.2020; 70(2): 404.     CrossRef
  • Basal cortisol levels and metabolic syndrome: A systematic review and meta-analysis of observational studies
    Anderson Garcez, Heloísa Marquardt Leite, Elisabete Weiderpass, Vera Maria Vieira Paniz, Guilherme Watte, Raquel Canuto, Maria Teresa Anselmo Olinto
    Psychoneuroendocrinology.2018; 95: 50.     CrossRef
  • Is salivary gland function altered in noninsulin-dependent diabetes mellitus and obesity–insulin resistance?
    Jitjiroj Ittichaicharoen, Nipon Chattipakorn, Siriporn C. Chattipakorn
    Archives of Oral Biology.2016; 64: 61.     CrossRef
  • The Role of Cortisol in the Pathogenesis of the Metabolic Syndrome
    In-Kyung Jeong
    Diabetes & Metabolism Journal.2012; 36(3): 207.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP